MedTrace Logo

Efficacy of Quetiapine for Pediatric Delirium

NCT02056171 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-12-13

Study results available
· View outcomes & findings →

Summary

This study is designed to assess the safety and efficacy of quetiapine as treatment for pediatric delirium.

Conditions

  • Delirium

Interventions

DRUG

quetiapine

Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.

OTHER

Placebo

Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Chani Traube, MD · Weill Medical College of Cornell University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02056171 on ClinicalTrials.gov